Desvenlafaxine is a new member of the SNRI class of antidepressants.
It is marketed as an extended release tablet for once-daily oral treatment
of MDD in adult patients. Desvenlafaxine (O-desmethylvenlafaxine) is
the major active metabolite of the previously marketed antidepressant
venlafaxine (Effexor). Similar to venlafaxine, desvenlafaxine is a more
potent inhibitor of serotonin and norepinephrine reuptake (IC50＝47 and
531 nM, respectively) than that of dopamine (62% inhibition at 100 mM)
in in vitro studies. It does not have significant in vitro affinity for other
neurotransmitter reporters such as a1-adrenergic, H1-histaminergic,
or muscarine-cholinergic receptors. Desvenlafaxine is marketed as a
racemic mixture. Specific pharmacological properties of the enantiomers
of desvenlafaxine have not been reported.
??? ??
White Solid
??
A metabolite of Venlafaxine, a selective serotonin noradrenaline reuptake inhibitor. Used as an antidepressant
??
ChEBI: A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.
?? ??
An analytical reference standard applicable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications such as urine drug testing, forensic analysis, or clinical toxicology. Also known as desvenlafaxine, O-desmethylvenlafaxine is an SNRI antidepressant marketed under the trade name Pristiq for the treatment of depression. O-desmethylvenlafaxine is also a major urinary metabolite of venlafaxine, an SNRI antidepressant sold as Effexor or Efexor and used to treat major depressive disorder, generalized anxiety disorder, and other anxiety disorders associated with depression.
